MARA Holdings
MARA
Tesla
TSLA
Petroleo Brasileiro SA Petrobras
PBR
4
Ecopetrol
EC
5
Vale SA
VALE
US Stock MarketDetailed Quotes
PROK ProKidney
- 0.7214
- +0.0214+3.06%
Close May 9 16:00 ET
- 0.7214
- 0.00000.00%
Post 20:01 ET
93.45MMarket Cap-1.16P/E (TTM)
0.7750High0.6820Low463.15KVolume0.7300Open0.7000Pre Close328.90KTurnover0.58%Turnover RatioLossP/E (Static)129.54MShares4.440052wk High-0.09P/B58.03MFloat Cap0.460352wk Low--Dividend TTM80.44MShs Float14.1900Historical High--Div YieldTTM13.29%Amplitude0.4603Historical Low0.7100Avg Price1Lot Size
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
ProKidney Stock Forum
From April 14
Carso De-C Inmobiliaria has made a significant investment in ProKidney by purchasing 1,034,118 shares of its stock. This transaction is valued at $620,470, highlighting a strong interest and confidence in ProKidney’s potential.
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
Positive
FDA confirmation that PROACT 1 Phase 3 study could be sufficient for full regulatory approval
Accelerated approval pathway available with eGFR slope as surrogate endpoint
Strong cash position of $406.8 million, supporting operations into 2027
Reduced R&D expenses by $0.9 million year-over-year
Slight improvement...
SEC· 11 mins ago
No comment yet